Enlivex (ENLV) Total Non-Current Liabilities (2015 - 2025)
Enlivex (ENLV) posted quarterly Total Non-Current Liabilities of $383.0 million for Q4 2025, up 128003.34% year-over-year from N/an in Q4 2024, and up 89812.91% quarter-over-quarter from $426000.0 in Q3 2025.
Enlivex (ENLV) Total Non-Current Liabilities (2015 - 2025) Analysis & Trends
Enlivex's Total Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $383.0 million for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 128003.34% year-over-year to $383.0 million; the TTM figure through Dec 2025 stood at $383.0 million (up 128003.34% YoY), while the FY2025 annual figure was $383.0 million, up 128003.34% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $383.0 million, up from $426000.0 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $383.0 million in Q4 2025, with the low at $216000.0 in Q2 2025.
- The 5-year median for Total Non-Current Liabilities is $2.2 million (2023), against an average of $21.4 million.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities slumped 89.03% in 2024, then surged 128003.34% in 2025.
- Enlivex's Total Non-Current Liabilities stood at $5.4 million in 2021, then dropped by 22.17% to $4.2 million in 2022, then slumped by 83.64% to $686000.0 in 2023, then sank by 56.41% to $299000.0 in 2024, then soared by 128003.34% to $383.0 million in 2025.
- Business Quant data shows ENLV's Total Non-Current Liabilities at $383.0 million in Q4 2025, $426000.0 in Q3 2025, and $216000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Enlivex | 4.58 Mn | -1.17 Mn | - | 383.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 383.03 Mn |
| Sep 30, 2025 | 426,000.00 |
| Jun 30, 2025 | 216,000.00 |
| Mar 31, 2025 | 264,000.00 |
| Dec 31, 2024 | 299,000.00 |
| Sep 30, 2024 | 419,000.00 |
| Jun 30, 2024 | 499,000.00 |
| Mar 31, 2024 | 587,000.00 |
| Dec 31, 2023 | 686,000.00 |
| Sep 30, 2023 | 3.82 Mn |
| Jun 30, 2023 | 3.70 Mn |
| Mar 31, 2023 | 4.00 Mn |
| Dec 31, 2022 | 4.19 Mn |
| Sep 30, 2022 | 4.61 Mn |
| Jun 30, 2022 | 4.64 Mn |
| Mar 31, 2022 | 5.23 Mn |
| Dec 31, 2021 | 5.39 Mn |
| Sep 30, 2021 | 5.35 Mn |
| Jun 30, 2021 | 405,000.00 |
| Mar 31, 2021 | 449,000.00 |